Platelet rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw: personal experience and review of the literature.
Platelet rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw: personal experience and review of the literature.
复制标题
DOI：
10.1155/2014/298945
复制
发表时间：
2014
影响因子：
2.1
通讯作者：
Ionna F
中科院分区：
文献类型：
--
作者：
Longo F;Guida A;Aversa C;Pavone E;Di Costanzo G;Ramaglia L;Ionna F
双膦酸盐（BP）是一类合成药物，常用于治疗骨转移和导致骨脆性的各种骨疾病（例如骨质疏松症）。双膦酸盐相关颌骨坏死 (BRONJ) 是接受 BP（尤其是静脉注射）患者的常见并发症。最近，有报道称不属于 BPs 药物类别的化疗药物引起颌骨坏死 (ONJ)。为此，最近有人提议将抗骨吸收药物相关颌骨坏死（ARONJ）中的BRONJ重新命名为BRONJ，以包括更广泛的可能导致颌骨坏死的药物。关于 ARONJ/BRONJ 最受争议的话题是治疗。最适当的程序远未标准化，预防似乎发挥着关键作用。在我们的研究中，我们对 72 名 BRONJ 患者进行了非手术治疗、手术治疗和富血小板血浆 (PRP) 凝胶手术治疗，以评估其促进 ONJ 伤口愈合的治疗效果。 PRP 在改善伤口愈合方面所显示的良好结果让病例对照随机研究可以提供其有效性的明确证据。
Bisphosphonates (BPs) are a class of synthetic drugs commonly used to treat bone metastasis and various bone diseases that cause osseous fragility (such as osteoporosis). Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a common complication in patients who received BPs, especially intravenously. Recently, osteonecrosis of the jaw (ONJ) caused by chemotherapeutic not belonging to BPs drug class has been reported. For this reason, it has been proposed recently to rename BRONJ in antiresorptive agents related osteonecrosis of the jaw (ARONJ), to include a wider spectrum of drugs that may cause osteonecrosis of the jaw. The most debated topic about ARONJ/BRONJ is therapy. The most adequate procedure is far from being standardized and prevention seems to play a pivotal role. In our study, we considered 72 patients with BRONJ with nonsurgical therapy, surgical therapy, and surgical therapy with platelet rich plasma (PRP) gel to evaluate its therapeutic effect in promoting ONJ wounds healing. Good results showed by PRP in improving wound healing give away to case-control randomized studies that could give definitive evidence of its effectiveness.